Evogene has appointed Dr Olga Nissan as its Vice President of Business Development, effective as of 1 January, 2026.

Dr Nissan is a seasoned biotechnology and pharmaceutical executive with experience in bridging science, business and funding. She has a proven track record of leading R&D, clinical development and business operations across the pharmaceutical, diagnostics and agri-biotechnology sectors. Her prior roles include CEO and Co-Founder of Protica Bio, Technology Manager at EcoPhage, Senior Scientist at BiomX and QC Domain Manager at Teva Pharmaceutical Industries.

"I am excited to join Evogene at a pivotal time in its expansion. The company's commitment to translating cutting-edge, AI-driven science into meaningful small-molecule-based therapeutic value, strongly aligns with my experience across pharma and biotech. I look forward to building strategic partnerships, advancing innovative discovery programmes, and working with Evogene's talented team to accelerate the delivery of impactful solutions for patients and partners worldwide," said Dr Olga Nissan.

Dr Nissan holds a PhD and completed postdoctoral research in the fields of biochemistry and proteomics, from the Weizmann Institute of Science.

Ofer Haviv, President and CEO, Evogene, added, "We are delighted to welcome Dr Olga Nissan to Evogene's leadership team. With more than 15 years of experience spanning biotech, pharma and AI-enabled drug discovery, Olga brings a unique combination of scientific depth, business development leadership and company-building expertise. We believe her capabilities will be instrumental as we scale our small-molecule discovery and optimisation offering, powered by our ChemPass AI tech-engine, and expand collaborations with leading industry partners - translating real-world innovation into meaningful value."